New Delhi: Senores Pharmaceuticals Limited has announced that it has received marketing authorizations from the Philippine Food and Drug Administration (FDA) for a portfolio of 10 products spanning Cardiovascular, Central Nervous System (CNS), and Pain Management therapies. This milestone marks a significant advancement in the company’s strategy to expand its footprint in Southeast Asia and improve access to affordable healthcare.
The approvals provide Senores Pharmaceuticals with a strong platform to serve the Philippines, where the market size of these drugs is valued at USD 23 million. This underscores the immense opportunity for growth and patient impact in the region.
Swapnil Shah, Managing Director of Senores Pharmaceuticals, stated: “These approvals reaffirm our commitment to delivering high-quality, affordable treatments for patients. Philippines is a critical market in our regional expansion strategy, and this achievement strengthens our position as a trusted partner in advancing healthcare.”
With these regulatory endorsements and strong manufacturing capabilities, Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region. The company aims to leverage its expertise, global partnerships, and uncompromising quality standards to:
- Improve treatment outcomes
- Broaden patient access to affordable medicines
- Strengthen its position as a reliable healthcare partner in emerging markets
This achievement highlights Senores Pharmaceuticals’ commitment to affordable healthcare solutions and its role in supporting regional health systems. By expanding into the Philippines, the company is set to contribute significantly to patient care in critical therapeutic areas.
